Omalizumab - nová možnost léčby chronické spontanní kopřivky, naše zkušenosti
| Title in English | Omalizumab - a new therapeutic modality for chronic spontaneous urticaria, our experience |
|---|---|
| Authors | |
| Year of publication | 2019 |
| Type | Article in Periodical |
| Magazine / Source | Remedia |
| Citation | |
| Keywords | chronic spontaneous urticaria – treatment - omalizumab |
| Description | Chronic spontaneous urticaria is a relatively common dermatological condition that significantly reduces the quality of life of patients. Recently, a new treatment method has been available for these patients in the form of a monoclonal antibody against the IgE molecule - omalizumab. The author describes his own experience with omalizumab treatment in a group of 17 patients with chronic spontaneous urticaria. The presence of thyroid disease and atopy has been significant in this group. The effect of treatment with omalizumab is assessed as very good, even if after discontinuation, the disease usually relapses. The response to omalizumab treatment, its degree, rate and duration of remission is, according to the author's knowledge, completely individual. |